Literature DB >> 19325144

Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells.

K C Y McGrath1, X H Li, R Puranik, E C Liong, J T M Tan, V M Dy, B A DiBartolo, P J Barter, K A Rye, A K Heather.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the ability of high-density lipoproteins (HDLs) to upregulate genes with the potential to protect against inflammation in endothelial cells. METHODS AND
RESULTS: Human coronary artery endothelial cells (HCAECs) were exposed to reconstituted HDLs (rHDLs) for 16 hours before being activated with tumor necrosis factor-alpha (TNF-alpha) for 5 hours. rHDLs decreased vascular cell adhesion molecule-1 (VCAM-1) promoter activity by 75% (P<0.05), via the nuclear factor-kappa B (NF-kappaB) binding site. rHDLs suppressed the canonical NF-kappaB pathway and decreased many NF-kappaB target genes. Suppression of NF-kappaB and VCAM-1 expression by rHDLs or native HDLs was dependent on an increase in 3beta-hydroxysteroid-Delta 24 reductase (DHCR24) levels (P<0.05). The effect of HDLs on DHCR24 is dependent on SR-BI but not ABCAI or ABCGI. Silencing DHCR24 expression increased NF-kappaB (1.2-fold, P<0.05), VCAM-1 (30-fold, P<0.05), and NF-kappaB p50 (4-fold, P<0.05) and p65 subunits (150-fold, P<0.05). TNF-alpha activation of siDHCR24-treated cells increased expression of VCAM-1 (550-fold, P<0.001) and NF-kappaB (9-fold, P<0.001) that could no longer be suppressed by rHDLs.
CONCLUSIONS: Results suggest that antiinflammatory effects of rHDLs are mediated partly through an upregulation of DHCR24. These findings raise the possibility of considering DHCR24 as a target for therapeutic modulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19325144     DOI: 10.1161/ATVBAHA.109.184663

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  31 in total

1.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

Review 2.  The emerging role of HDL in glucose metabolism.

Authors:  Brian G Drew; Kerry-Anne Rye; Stephen J Duffy; Philip Barter; Bronwyn A Kingwell
Journal:  Nat Rev Endocrinol       Date:  2012-01-24       Impact factor: 43.330

3.  Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants.

Authors:  Alexander K Tsai; Brian T Steffen; Jose M Ordovas; Robert Straka; Xia Zhou; Naomi Q Hanson; Donna Arnett; Michael Y Tsai
Journal:  Transl Res       Date:  2011-02-26       Impact factor: 7.012

Review 4.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

5.  HDL inhibits the effects of oxidized phospholipids on endothelial cell gene expression via multiple mechanisms.

Authors:  Benjamin Emert; Yehudit Hasin-Brumshtein; James R Springstead; Ladan Vakili; Judith A Berliner; Aldons J Lusis
Journal:  J Lipid Res       Date:  2014-05-23       Impact factor: 5.922

6.  Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

Authors:  Laurent Yvan-Charvet; Jelena Kling; Tamara Pagler; Hongna Li; Brian Hubbard; Tim Fisher; Carl P Sparrow; Andrew K Taggart; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

Review 7.  Genetic alterations affecting cholesterol metabolism and human fertility.

Authors:  Anthony M DeAngelis; Meaghan Roy-O'Reilly; Annabelle Rodriguez
Journal:  Biol Reprod       Date:  2014-08-13       Impact factor: 4.285

Review 8.  HDL and endothelial protection.

Authors:  A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells.

Authors:  Fatiha Tabet; Kasey C Vickers; Luisa F Cuesta Torres; Carrie B Wiese; Bassem M Shoucri; Gilles Lambert; Claire Catherinet; Leonel Prado-Lourenco; Michael G Levin; Seth Thacker; Praveen Sethupathy; Philip J Barter; Alan T Remaley; Kerry-Anne Rye
Journal:  Nat Commun       Date:  2014-02-28       Impact factor: 14.919

10.  Signaling regulates activity of DHCR24, the final enzyme in cholesterol synthesis.

Authors:  Winnie Luu; Eser J Zerenturk; Ika Kristiana; Martin P Bucknall; Laura J Sharpe; Andrew J Brown
Journal:  J Lipid Res       Date:  2013-12-20       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.